NCT03717350 is a Phase 2, PHASE3 clinical trial of Meropenem in Sepsis, sponsored by Hellenic Institute for the Study of Sepsis.

Who is sponsoring NCT03717350?

NCT03717350 is sponsored by Hellenic Institute for the Study of Sepsis.

What drugs are being tested in NCT03717350?

Interventions in NCT03717350: Meropenem, Placebo.

Is NCT03717350 still recruiting?

NCT03717350 is currently status unknown. Last updated 30 July 2020.

Last reviewed 2020-07-30 · How we verify

NCT03717350

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

suPAR to Guide Antibiotics in Emergency Department

Status unknown Phase 2, PHASE3 Last updated 30 July 2020

What this trial tests

Phase 2, PHASE3 trial testing Meropenem in Sepsis in 220 participants. Status unknown.

Timeline

27 October 2018

Primary endpoint
31 July 2021

31 August 2021

Quick facts

Lead sponsor	Hellenic Institute for the Study of Sepsis
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	220
Start date	27 October 2018
Primary completion	31 July 2021
Estimated completion	31 August 2021
Sites	5 locations across Greece

Drugs / interventions tested

Meropenem (Meropenem) — full drug profile →
Placebo

Conditions studied

Sepsis — all drugs for Sepsis →

Sponsor

Hellenic Institute for the Study of Sepsis

Who can join

18 and older, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the current study is to evaluate suPAR - guided medical intervention, consisting of early antibiotic administration at the emergency room for presumed infection and sepsis and evaluate the impact of this intervention to the patients' final outcome. Since the traditionally used biomarkers (PCT, CRP) and scores (SOFA score) for early recognition of severity of infection fail to achieve maximum accuracy in all cases, suPAR levels are assessed as a probably better prognostic rule for early recognition of severe infections. The primary study endpoint will be the comparative efficacy of the early suPAR-guided administration of antibiotics versus standard practice on 28-day mortality.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group.
Velissaris D, Dimopoulos G, Parissis J, Alexiou Z, et al · · 2020 · cited 20× · PMID 32399855 · DOI 10.1007/s40121-020-00301-w
qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial.
Adami ME, Kotsaki A, Antonakos N, Giannitsioti E, et al · · 2024 · cited 15× · PMID 38321472 · DOI 10.1186/s13054-024-04825-2

Verify or expand the search:

Other trials of Meropenem

Trials testing the same drug.

NCT06184659 — Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis · Phase 4 · recruiting
NCT07445282 — This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Me · Phase 4 · completed
NCT06916156 — Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants · Phase 1 · completed
NCT06527677 — Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects · Phase 1 · completed
NCT05905913 — FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects · Phase 1 · completed

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other Hellenic Institute for the Study of Sepsis trials

Trials by the same sponsor.

NCT06608849 — The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acut · recruiting
NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
NCT07073456 — Viscoelastic Coagulation for Early Sepsis Detection · recruiting
NCT06294600 — Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) · Phase 3 · recruiting
NCT06141395 — NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03717350 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hellenic Institute for the Study of Sepsis
Last refreshed: 30 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03717350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing